As of April 16, 2026, Assure Holdings (IONM) is trading at $0.0005 USD, indicating significant market challenges and valuation pressure. The company operates in a specialized surgical support niche, competing against established players but facing profitability hurdles with EPS of -$206.28 for the trailing twelve months.
Cyborg Score Rationale
Assure Holdings faces severe operational and financial headwinds, evidenced by negative earnings, micro-cap market valuation, and an extremely depressed stock price as of April 2026. The company operates in a legitimate surgical support market but struggles with scale, profitability, and shareholder value creation.
Top Insights
Trailing twelve-month revenue of $87K reflects minimal commercial traction despite operating in a specialized surgical support market, raising questions about market penetration and execution capabilities.
Assure Holdings has 103 total employees deployed across neurosurgery, spine, cardiovascular, and orthopedic surgical support, but revenue-per-employee metrics remain dramatically depressed, signaling operational inefficiency.
Assure Holdings competes against Accurate Monitoring, SpecialtyCare, Neuromonitoring Technologies, CortiCare, and Medsurant Monitoring in a fragmented IONM market, but lacks the financial resources and scale of larger rivals.
Named Competitors
Accurate Monitoring — Intraoperative neuromonitoring services
SpecialtyCare — IONM surgical support services
Neuromonitoring Technologies — Neurophysiological monitoring for surgery